市場調査レポート

商品コード

分子感染症検査の世界市場：製品・サービス別、タイプ別、検査タイプ別、疾患別、技術別、エンドユーザー別 - 予測（～2029年）

Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2029

出版日: 2025年02月13日
発行: MarketsandMarkets
ページ情報: 英文 449 Pages
納期: 即納可能

カスタマイズ可能

価格

PDF (Single User License)

USD 4,950 710,671円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (5-user License)

USD 6,650 954,740円

レポートPDFを同じ国内の同じ事業所内の5名迄にて共有ご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Corporate License)

USD 8,150 1,170,095円

レポートPDFを企業内すべての方に使用頂けるライセンスです。ご利用人数の制限はありませんが、同一国内にある事業所のみとなり、海外支店などは含まれません。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Global License)

USD 10,000 1,435,700円

レポートPDFを同一企業の全世界の方にご使用頂けるライセンスです。ご利用人数に制限はありません。100％子会社は同一企業とみなされます。PDF内のテキスト等のコピー＆ペースト可能です。PDの印刷は何回でも可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界の分子感染症検査の市場規模は、2024年の推定93億7,000万米ドルから2029年までに177億8,000万米ドルに達すると予測され、予測期間にCAGRで13.7%の成長が見込まれます。

分子診断技術の急速な進歩が市場の主な促進要因です。PCR、次世代シーケンシング、その他の技術の進歩により、検査の精度、完了までのスピード、効率が向上し、低コストでより利用しやすくなっています。さらに、参入企業はワークフローをさらに改善し、診断能力を高めるハイエンド自動診断プラットフォームの開発を続けています。これにより、感染症の正確かつタイムリーな診断、患者の検査結果の改善、新たに登場した病原体の監視の向上がもたらされます。これにより、医療提供者はタイムリーな意思決定が可能となり、感染症検査における分子診断の採用率が高まっています。

調査範囲
調査対象年	2022年～2029年
基準年	2023年
予測期間	2024年～2029年
単位	米ドル
セグメント	製品・サービス、タイプ、検査タイプ、疾患、技術、エンドユーザー
対象地域	北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカ、GCC諸国

「検査タイプ別では、臨床検査セグメントが予測期間に市場でもっとも速い成長率を示見込みです。」

臨床検査は、精度が高く、拡張性があり、あらゆる種類の病原体を扱うことができるため、分子感染症検査市場において検査タイプ別でもっとも急成長しているセグメントです。PCRやシーケンシングベースの診断を含むこれらの検査は、感染症の発見における精度の高さから、病院や診断検査室で広く使用されています。検査室の自動化とハイスループット技術の進歩により、検査にかかる時間は大幅に短縮され、検査室ベース分子検査は非常に効率的なものとなっています。さらに、1回の検査で複数の感染症を検出できる広範な診断パネルへのニーズが、検査室ベースのソリューションへの選好をさらに高めています。信頼性が高く、複雑な診断ニーズに対応できる臨床検査は、医療提供者に好まれるソリューションです。

「タイプ別では、マルチプレックス検査セグメントが2023年に最大の市場シェアを占めました。」

マルチプレックス検査は、1回の検査で複数の病原体を検出・鑑別することができるため、市場をリードしています。この効率性により、診断にかかる時間、コスト、リソースを削減できるため、医療提供者にもっとも好まれる選択肢の1つとなっています。これらの要因に加え、重複感染の増加、徹底的な診断ソリューションの必要性、タイムリーで正確な結果に対する需要が、マルチプレックス検査市場を拡大しています。さらに、新技術の改良には、アッセイ感度の向上や、病院や診断検査室でのマルチプレックス検査の普及を支える使いやすいプラットフォームの導入が含まれます。

「アジア太平洋：もっとも速く成長している分子感染症検査市場」

アジア太平洋は、人口密度の高い国々における感染症の罹患率の増加と、疾患の早期発見に対する意識の高まりにより、先進の診断薬に対する需要が高まり、分子感染症検査市場が大きく成長しています。この地域の政府や医療機関は、医療インフラの改善、診断能力の拡大、研究活動の支援に多額の投資を行っています。さらに、疾病の監視と発生管理が重視されるようになり、医療費も増加していることから、アジア太平洋は市場全体の成長に大きく寄与する地域の1つとなっています。

当レポートでは、世界の分子感染症検査市場について調査分析し、主な促進要因と抑制要因、競合情勢、将来の動向などの情報を提供しています。

分子感染症検査市場の概要
分子感染症検査市場：製品・サービス別（2024年・2029年）
分子感染症検査市場：タイプ別（2024年・2029年）
分子感染症検査市場：検査タイプ別（2024年・2029年）
分子感染症検査市場：疾患別（2024年・2029年）
分子感染症検査市場：技術別（2024年・2029年）
分子感染症検査市場：エンドユーザー別（2024年・2029年）
分子感染症検査市場：地理的成長機会

第5章市場の概要

イントロダクション
市場力学
- 促進要因
- 抑制要因
- 機会
- 課題
顧客ビジネスに影響を与える動向/混乱
価格分析
- 参考販売価格の動向：製品別
- 性感染症検査の参考販売価格の動向：主要企業別
- 消化器疾患検査の参考販売価格の動向：主要企業別
- 参考販売価格の動向：地域別
バリューチェーン分析
サプライチェーン分析
エコシステム分析
投資と資金調達のシナリオ
技術分析
- 主要技術
- 補完技術
- 隣接技術
特許分析
貿易分析
- HSコード3822の輸入データ
- HSコード3822の輸出データ
主な会議とイベント（2025年～2026年）
ケーススタディ分析
規制情勢
- 規制分析
- 規制機関、政府機関、その他の組織
ポーターのファイブフォース分析
主なステークホルダーと購入基準
分子感染症検査市場に対するAIの影響
- イントロダクション
- 分子感染症検査用途におけるAIの市場可能性
- AIのユースケース
- AIを導入している主要企業
- 分子感染症検査市場におけるAIの未来

第6章分子感染症検査市場：製品・サービス別

イントロダクション
試薬・キット
器具
サービス・ソフトウェア

第7章分子感染症検査市場：タイプ別

イントロダクション
マルチプレックス検査
シングルプレックス検査

第8章分子感染症検査市場：検査タイプ別

イントロダクション
臨床検査
ポイントオブケア検査

第9章分子感染症検査市場：疾患別

イントロダクション
呼吸器感染症
消化器感染症
性感染症
院内感染
膣炎
髄膜炎
媒介性感染症
その他の感染症

第10章分子感染症検査市場：技術別

イントロダクション
ポリメラーゼ連鎖反応
等温核酸増幅技術
DNAシーケンシング・次世代シーケンシング
in situハイブリダイゼーション
DNAマイクロアレイ
その他の技術

第11章分子感染症検査市場：エンドユーザー別

イントロダクション
診断検査室
病院・診療所
その他のエンドユーザー

第12章分子感染症検査市場：地域別

イントロダクション
北米
- 北米のマクロ経済の見通し
- 米国
- カナダ
欧州
- 欧州のマクロ経済の見通し
- ドイツ
- 英国
- フランス
- イタリア
- ロシア
- スペイン
- その他の欧州
アジア太平洋
- アジア太平洋のマクロ経済の見通し
- 中国
- 日本
- インド
- オーストラリア
- その他のアジア太平洋
ラテンアメリカ
- ラテンアメリカのマクロ経済の見通し
- ブラジル
- メキシコ
- その他のラテンアメリカ
中東・アフリカ
GCC諸国

第13章競合情勢

イントロダクション
主要参入企業の戦略/強み
収益分析（2021年～2023年）
市場シェア分析（2023年）
欧州・中東・アフリカの市場シェア分析（2023年）
企業の評価と財務指標
ブランド/製品の比較
企業の評価マトリクス：主要企業（2023年）
企業の評価マトリクス：スタートアップ/中小企業（2023年）
競合シナリオ

第14章企業プロファイル

主要企業
- DANAHER
- F. HOFFMANN-LA ROCHE LTD
- BIOMERIEUX
- HOLOGIC, INC.
- ABBOTT
- THERMO FISHER SCIENTIFIC INC.
- QIAGEN
- REVVITY
- GRIFOLS, S.A.
- SEEGENE INC.
- DIASORIN S.P.A.
- SIEMENS HEALTHINEERS AG
- BD
その他の企業
- QUIDELORTHO CORPORATION
- BRUKER
- GENETIC SIGNATURES
- CO-DIAGNOSTICS, INC.
- VELA DIAGNOSTICS
- MOLBIO DIAGNOSTICS PVT. LTD.
- SAVYON DIAGNOSTICS
- UNIOGEN OY
- GENEOMBIO TECHNOLOGIES
- ADVANCED MOLECULAR DIAGNOSTICS
- ALTONA DIAGNOSTICS GMBH
- GENEFIRST LIMITED

第15章付録

図表

List of Tables

TABLE 1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: INCLUSIONS AND EXCLUSIONS
TABLE 2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: KEY DATA FROM PRIMARY SOURCES
TABLE 3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: RISK ANALYSIS
TABLE 4 GLOBAL HIV DATA, 2020 VS. 2022 VS. 2023
TABLE 5 INDICATIVE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, 2022-2024
TABLE 6 INDICATIVE SELLING PRICE TREND OF SEXUALLY TRANSMITTED DISEASE TESTS, BY KEY PLAYER, 2022-2024
TABLE 7 INDICATIVE SELLING PRICE TREND OF GASTROINTESTINAL INFECTIOUS DISEASE TESTS, BY KEY PLAYER, 2022-2024
TABLE 8 INDICATIVE SELLING PRICE TREND OF MOLECULAR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2022-2024
TABLE 9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ROLE OF COMPANIES IN ECOSYSTEM
TABLE 10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022-2023
TABLE 11 IMPORT DATA FOR HS CODE 3822 (DIAGNOSTIC AND LABORATORY REAGENTS), BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 12 EXPORT DATA FOR HS CODE 3822 (DIAGNOSTIC AND LABORATORY REAGENTS), BY COUNTRY, 2019-2023 (USD MILLION)
TABLE 13 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: KEY CONFERENCES AND EVENTS, 2025-2026
TABLE 14 CLASSIFICATION OF IVD DEVICES IN EUROPE
TABLE 15 TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS IN JAPAN
TABLE 16 CLASSIFICATION OF IVD MEDICAL DEVICES IN AUSTRALIA
TABLE 17 NORTH AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 18 EUROPE: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 19 ASIA PACIFIC: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 20 LATIN AMERICA: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 21 REST OF THE WORLD: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 22 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
TABLE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
TABLE 24 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
TABLE 25 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 26 KEY REAGENTS & KITS AVAILABLE IN MARKET
TABLE 27 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY REGION, 2022-2029 (USD MILLION)
TABLE 28 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 29 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 30 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 31 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR REAGENTS & KITS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 32 KEY TESTING INSTRUMENTS AVAILABLE IN MARKET
TABLE 33 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 34 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 35 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 36 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 37 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INSTRUMENTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 38 KEY SOFTWARE SOLUTIONS AVAILABLE IN MARKET
TABLE 39 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY REGION, 2022-2029 (USD MILLION)
TABLE 40 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 41 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 42 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 43 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 44 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 45 KEY MULTIPLEX TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 46 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY REGION, 2022-2029 (USD MILLION)
TABLE 47 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 48 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 49 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 50 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MULTIPLEX TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 51 KEY SINGLEPLEX TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 52 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY REGION, 2022-2029 (USD MILLION)
TABLE 53 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 54 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 55 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 56 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SINGLEPLEX TESTING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 57 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 58 KEY LABORATORY-BASED TESTS AND DEVICES AVAILABLE IN MARKET
TABLE 59 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 60 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 61 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 62 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 63 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR LABORATORY TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 64 KEY POINT OF CARE TESTS AND DEVICES AVAILABLE IN MARKET
TABLE 65 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY REGION, 2022-2029 (USD MILLION)
TABLE 66 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 67 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 68 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 69 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POINT OF CARE TESTS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 70 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 71 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 72 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 73 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 74 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 75 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 76 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 77 KEY INFLUENZA TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 78 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY REGION, 2022-2029 (USD MILLION)
TABLE 79 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 80 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 81 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 82 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR INFLUENZA, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 83 KEY TUBERCULOSIS TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 84 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 85 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 86 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2029 (IN THOUSANDS)
TABLE 87 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 88 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 89 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 90 KEY PHARYNGITIS TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 91 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 92 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 93 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 94 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 95 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR PHARYNGITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 96 OTHER KEY RESPIRATORY INFECTION DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 97 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 98 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 99 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 100 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 101 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER RESPIRATORY INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 102 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 103 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 104 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 105 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 106 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 107 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 108 KEY HEPATITIS TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 109 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 110 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 111 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (IN THOUSANDS)
TABLE 112 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 113 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 114 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HEPATITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 115 OTHER KEY GASTROINTESTINAL INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 116 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 117 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 118 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 119 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 120 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER GASTROINTESTINAL INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 121 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 122 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 123 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 124 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 125 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 126 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 127 KEY HIV TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 128 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY REGION, 2022-2029 (USD MILLION)
TABLE 129 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 130 NORTH AMERICA: MOLECULAR INFECTIOUS TESTING MARKET FOR HIV, BY COUNTRY, 2022-2029 (IN THOUSANDS)
TABLE 131 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 132 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 133 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HIV, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 134 KEY HUMAN PAPILLOMAVIRUS TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 135 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY REGION, 2022-2029 (USD MILLION)
TABLE 136 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 137 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 138 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 139 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HUMAN PAPILLOMAVIRUS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 140 KEY CHLAMYDIA TRACHOMATIS TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 141 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 142 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 143 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 144 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 145 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR CHLAMYDIA TRACHOMATIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 146 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY REGION, 2022-2029 (USD MILLION)
TABLE 147 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 148 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 149 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 150 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR NEISSERIA GONORRHOEAE, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 151 KEY SYPHILIS TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 152 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 153 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 154 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 155 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 156 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SYPHILIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 157 OTHER KEY SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 158 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 159 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 160 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 161 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 162 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER SEXUALLY TRANSMITTED DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 163 KEY HOSPITAL-ACQUIRED INFECTION TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 164 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2022-2029 (USD MILLION)
TABLE 165 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 166 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 167 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 168 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITAL-ACQUIRED INFECTIONS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 169 KEY VAGINITIS TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 170 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 171 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 172 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 173 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 174 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VAGINITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 175 KEY MENINGITIS TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 176 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY REGION, 2022-2029 (USD MILLION)
TABLE 177 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 178 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 179 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 180 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR MENINGITIS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 181 KEY VECTOR-BORNE DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 182 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 183 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 184 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 185 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 186 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR VECTOR-BORNE DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 187 OTHER KEY INFECTIOUS DISEASE TESTING PRODUCTS AVAILABLE IN MARKET
TABLE 188 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY REGION, 2022-2029 (USD MILLION)
TABLE 189 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 190 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 191 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 192 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER INFECTIOUS DISEASES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 193 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 194 KEY POLYMERASE CHAIN REACTION-BASED TESTS AND DEVICES AVAILABLE IN MARKET
TABLE 195 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022-2029 (USD MILLION)
TABLE 196 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 197 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 198 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 199 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 200 KEY ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY-BASED TESTS AND DEVICES AVAILABLE IN MARKET
TABLE 201 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY REGION, 2022-2029 (USD MILLION)
TABLE 202 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 203 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 204 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 205 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 206 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY REGION, 2022-2029 (USD MILLION)
TABLE 207 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 208 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 209 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 210 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA SEQUENCING & NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 211 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022-2029 (USD MILLION)
TABLE 212 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 213 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 214 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 215 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 216 KEY MICROARRAY-BASED PRODUCTS AVAILABLE IN MARKET
TABLE 217 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY REGION, 2022-2029 (USD MILLION)
TABLE 218 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 219 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 220 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 221 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DNA MICROARRAYS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 222 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 223 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 224 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 225 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 226 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 227 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 228 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
TABLE 229 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 230 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 231 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 232 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 233 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022-2029 (USD MILLION)
TABLE 234 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 235 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 236 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 237 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 238 MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
TABLE 239 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 240 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 241 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 242 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR OTHER END USERS, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 243 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
TABLE 244 MACROECONOMIC INDICATORS FOR NORTH AMERICA
TABLE 245 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 246 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 247 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 248 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 249 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 250 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 251 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 252 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 253 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 254 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 255 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 256 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 257 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 258 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 259 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 260 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 261 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 262 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 263 US: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 264 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 265 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 266 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 267 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 268 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 269 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 270 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 271 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 272 CANADA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 273 MACROECONOMIC INDICATORS FOR EUROPE
TABLE 274 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 275 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 276 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 277 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 278 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 279 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 280 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 281 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 282 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 283 EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 284 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 285 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 286 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 287 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 288 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 289 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 290 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 291 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 292 GERMANY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 293 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 294 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 295 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 296 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 297 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 298 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 299 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 300 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 301 UK: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 302 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 303 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 304 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 305 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 306 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 307 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 308 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 309 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 310 FRANCE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 311 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 312 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 313 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 314 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 315 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 316 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 317 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 318 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 319 ITALY: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 320 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 321 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 322 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 323 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 324 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 325 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 326 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 327 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 328 RUSSIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 329 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 330 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 331 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 332 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 333 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 334 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 335 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 336 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 337 SPAIN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 338 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 339 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 340 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 341 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 342 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 343 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 344 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 345 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 346 REST OF EUROPE: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 347 MACROECONOMIC INDICATORS FOR ASIA PACIFIC
TABLE 348 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 349 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 350 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 351 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 352 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 353 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 354 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 355 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 356 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 357 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 358 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 359 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 360 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 361 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 362 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 363 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 364 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 365 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 366 CHINA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 367 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 368 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 369 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 370 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 371 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 372 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 373 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 374 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 375 JAPAN: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 376 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 377 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 378 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 379 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 380 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 381 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 382 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 383 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 384 INDIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 385 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 386 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 387 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 388 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 389 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 390 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 391 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 392 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 393 AUSTRALIA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 394 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 395 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 396 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 397 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 398 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 399 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 400 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 401 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 402 REST OF ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 403 MACROECONOMIC INDICATORS FOR LATIN AMERICA
TABLE 404 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
TABLE 405 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 406 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 407 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 408 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 409 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 410 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 411 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 412 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 413 LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 414 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 415 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 416 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 417 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 418 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 419 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 420 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 421 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 422 BRAZIL: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 423 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 424 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 425 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 426 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 427 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 428 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 429 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 430 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 431 MEXICO: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 432 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 433 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 434 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 435 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 436 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 437 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 438 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 439 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 440 REST OF LATIN AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 441 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 442 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 443 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 444 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 445 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 446 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 447 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 448 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 449 MIDDLE EAST & AFRICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 450 MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA
TABLE 451 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2022-2029 (USD MILLION)
TABLE 452 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2022-2029 (USD MILLION)
TABLE 453 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2022-2029 (USD MILLION)
TABLE 454 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2022-2029 (USD MILLION)
TABLE 455 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR RESPIRATORY INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 456 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR GASTROINTESTINAL INFECTIOUS DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 457 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET FOR SEXUALLY TRANSMITTED DISEASES, BY TYPE, 2022-2029 (USD MILLION)
TABLE 458 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
TABLE 459 GCC COUNTRIES: MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
TABLE 460 MACROECONOMIC INDICATORS FOR GCC COUNTRIES
TABLE 461 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, JANUARY 2021-DECEMBER 2024
TABLE 462 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEGREE OF COMPETITION
TABLE 463 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: REGION FOOTPRINT
TABLE 464 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT & SERVICE FOOTPRINT
TABLE 465 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TEST TYPE FOOTPRINT
TABLE 466 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DISEASE FOOTPRINT
TABLE 467 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 468 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
TABLE 469 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
TABLE 470 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 471 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 472 DANAHER: COMPANY OVERVIEW
TABLE 473 DANAHER: PRODUCTS OFFERED
TABLE 474 DANAHER: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 475 DANAHER: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 476 DANAHER: EXPANSIONS, JANUARY 2021-DECEMBER 2024
TABLE 477 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW
TABLE 478 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
TABLE 479 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 480 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 481 F. HOFFMANN-LA ROCHE LTD: EXPANSIONS, JANUARY 2021-DECEMBER 2024
TABLE 482 BIOMERIEUX: COMPANY OVERVIEW
TABLE 483 BIOMERIEUX: PRODUCTS OFFERED
TABLE 484 BIOMERIEUX: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 485 BIOMERIEUX: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 486 HOLOGIC, INC.: COMPANY OVERVIEW
TABLE 487 HOLOGIC, INC.: PRODUCTS OFFERED
TABLE 488 HOLOGIC, INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 489 HOLOGIC, INC.: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 490 ABBOTT: COMPANY OVERVIEW
TABLE 491 ABBOTT: PRODUCTS OFFERED
TABLE 492 ABBOTT: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 493 ABBOTT: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 494 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 495 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 496 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 497 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 498 QIAGEN: COMPANY OVERVIEW
TABLE 499 QIAGEN: PRODUCTS OFFERED
TABLE 500 QIAGEN: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 501 QIAGEN: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 502 QIAGEN: EXPANSIONS, JANUARY 2021-DECEMBER 2024
TABLE 503 REVVITY: COMPANY OVERVIEW
TABLE 504 REVVITY: PRODUCTS OFFERED
TABLE 505 GRIFOLS, S.A.: COMPANY OVERVIEW
TABLE 506 GRIFOLS, S.A.: PRODUCTS OFFERED
TABLE 507 GRIFOLS, S.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 508 GRIFOLS, S.A.: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 509 SEEGENE INC.: COMPANY OVERVIEW
TABLE 510 SEEGENE INC.: PRODUCTS OFFERED
TABLE 511 SEEGENE INC.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 512 SEEGENE INC.: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 513 SEEGENE INC.: EXPANSIONS, JANUARY 2021-DECEMBER 2024
TABLE 514 DIASORIN S.P.A.: COMPANY OVERVIEW
TABLE 515 DIASORIN S.P.A.: PRODUCTS OFFERED
TABLE 516 DIASORIN S.P.A.: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 517 DIASORIN S.P.A.: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 518 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
TABLE 519 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
TABLE 520 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 521 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 522 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021-DECEMBER 2024
TABLE 523 BD: COMPANY OVERVIEW
TABLE 524 BD: PRODUCTS OFFERED
TABLE 525 BD: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2021-DECEMBER 2024
TABLE 526 BD: DEALS, JANUARY 2021-DECEMBER 2024
TABLE 527 BD: EXPANSIONS, JANUARY 2021-DECEMBER 2024
TABLE 528 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
TABLE 529 BRUKER: COMPANY OVERVIEW
TABLE 530 GENETIC SIGNATURES: COMPANY OVERVIEW
TABLE 531 CO-DIAGNOSTICS, INC.: COMPANY OVERVIEW
TABLE 532 VELA DIAGNOSTICS: COMPANY OVERVIEW
TABLE 533 MOLBIO DIAGNOSTICS PVT. LTD.: COMPANY OVERVIEW
TABLE 534 SAVYON DIAGNOSTICS: COMPANY OVERVIEW
TABLE 535 UNIOGEN OY: COMPANY OVERVIEW
TABLE 536 GENEOMBIO TECHNOLOGIES: COMPANY OVERVIEW
TABLE 537 ADVANCED MOLECULAR DIAGNOSTICS: COMPANY OVERVIEW
TABLE 538 ALTONA DIAGNOSTICS: COMPANY OVERVIEW
TABLE 539 GENEFIRST LIMITED: COMPANY OVERVIEW

List of Figures

FIGURE 1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET SEGMENTATION AND REGIONS COVERED
FIGURE 2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: RESEARCH DESIGN
FIGURE 3 KEY INDUSTRY INSIGHTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
FIGURE 8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: TOP-DOWN APPROACH
FIGURE 9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DATA TRIANGULATION
FIGURE 10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PARAMETRIC ASSUMPTIONS
FIGURE 11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
FIGURE 12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 13 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 14 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024 VS. 2029 (USD MILLION)
FIGURE 15 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
FIGURE 16 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
FIGURE 17 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
FIGURE 18 RISING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET
FIGURE 19 REAGENTS & KITS SEGMENT TO DOMINATE MARKET IN 2029
FIGURE 20 MULTIPLEX TESTING SEGMENT TO HAVE LARGEST MARKET SHARE IN 2029
FIGURE 21 LABORATORY TESTS TO HOLD LARGEST MARKET SHARE IN 2029
FIGURE 22 SEXUALLY TRANSMITTED DISEASES SEGMENT TO LEAD MARKET IN 2029
FIGURE 23 POLYMERASE CHAIN REACTION SEGMENT TO HAVE LARGEST MARKET SHARE IN 2029
FIGURE 24 DIAGNOSTIC LABORATORIES SEGMENT TO COMMAND LARGEST MARKET SHARE IN 2029
FIGURE 25 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
FIGURE 26 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 27 NEW REVENUE POCKETS FOR PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
FIGURE 28 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: VALUE CHAIN ANALYSIS
FIGURE 29 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 30 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: ECOSYSTEM ANALYSIS
FIGURE 31 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: INVESTMENT AND FUNDING SCENARIO, 2021-2024
FIGURE 32 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PATENT ANALYSIS, JANUARY 2014-DECEMBER 2023
FIGURE 33 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 34 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
FIGURE 35 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
FIGURE 36 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING APPLICATIONS
FIGURE 37 REGIONAL INCIDENCE OF HIV, 2023
FIGURE 38 NORTH AMERICA: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT
FIGURE 39 ASIA PACIFIC: MOLECULAR INFECTIOUS DISEASE TESTING MARKET SNAPSHOT
FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2021-2023
FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023
FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN EMEA REGION IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET, 2023
FIGURE 43 EV/EBITDA OF KEY VENDORS, 2024
FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2024
FIGURE 45 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: BRAND/PRODUCT COMPARISON
FIGURE 46 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
FIGURE 47 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY FOOTPRINT
FIGURE 48 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
FIGURE 49 DANAHER: COMPANY SNAPSHOT (2023)
FIGURE 50 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023)
FIGURE 51 BIOMERIEUX: COMPANY SNAPSHOT (2023)
FIGURE 52 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
FIGURE 53 ABBOTT: COMPANY SNAPSHOT (2023)
FIGURE 54 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
FIGURE 55 QIAGEN: COMPANY SNAPSHOT (2023)
FIGURE 56 REVVITY: COMPANY SNAPSHOT (2023)
FIGURE 57 GRIFOLS, S.A.: COMPANY SNAPSHOT (2023)
FIGURE 58 SEEGENE INC.: COMPANY SNAPSHOT (2023)
FIGURE 59 DIASORIN S.P.A.: COMPANY SNAPSHOT (2023)
FIGURE 60 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
FIGURE 61 BD: COMPANY SNAPSHOT (2024)

Product Code: MD 9285

The molecular infectious disease testing market is projected to reach USD 17.78 billion in 2029 from an estimated value of USD 9.37 billion in 2024 at a CAGR of 13.7% during the forecast period. Rapid advancements in molecular diagnostic technologies are the main driving force in the molecular infectious disease testing market. Advancements in PCR, next-generation sequencing, and other technologies enhance test accuracy, speed of completion, and efficiency, making them more accessible at lower costs. Moreover, market players continue to develop high- end automated diagnostic platforms which further improves the workflow and increases diagnostic capabilities. This leads to accurate and timely diagnosis of infectious diseases, improved patient results, and improved surveillance of newly emerging pathogens. Through this, providers can make timely decisions, increasing the adoption rate of molecular diagnostics for infectious disease testing.

Scope of the Report
Years Considered for the Study	2022-2029
Base Year	2023
Forecast Period	2024-2029
Units Considered	Value (USD)
Segments	Product & Service, Type, Test Type, Disease, Technology, and End User
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC Countries

"Laboratory tests segment is expected to witness the fastest growth rate in the molecular infectious disease testing market, by test type, during the forecast period."

Based on test type, the molecular infectious disease testing market can be divided into laboratory tests and point of care tests. Laboratory tests are the fastest-growing segment by test type in the molecular infectious disease testing market because of their high accuracy, scalability, and ability to handle all types of pathogens. These tests, including PCR and sequencing-based diagnostics, are widely used in hospitals and diagnostic laboratories for their precision in discovering infections. With the advances in laboratory automation and high-throughput technologies, turnaround times have decreased significantly, thereby making the laboratory-based molecular tests very efficient. Moreover, the need for extensive diagnostic panels that allow detection of multiple infections in one test further enhances the preference for laboratory-based solutions. With high reliability and the capability to address complex diagnostic needs, laboratory tests are the preferred solution for healthcare providers.

"Multiplex testing segment accounted for the largest market share in the molecular infectious disease testing market, by type, in 2023."

Based on type, the molecular infectious disease testing market is bifurcated into singleplex testing and multiplex testing. The multiplex testing segment leads the molecular infectious disease testing market due to the capability of its ability to perform multiple tests for detecting and differentiating several pathogens in a single test. This efficiency cuts down time, costs, and resources for diagnosis, thus becoming one of the most preferred options by healthcare providers. All these factors together with the rise in co-infections, necessity for thorough diagnosis solutions, and demand for timely and accurate results have increased the multiplex testing market. In addition, new technology improvements include greater assay sensitivity and the introduction of user-friendly platforms that support widespread use of multiplex testing in hospitals and diagnostic labs.

"Asia Pacific: The fastest-growing market for molecular infectious disease testing"

The worldwide market for molecular infectious disease testing is categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The Asia Pacific region is experiencing significant growth in the molecular infectious disease testing market driven by the growing incidence of infectious diseases in the densely populated countries, together with growing awareness of the early detection of diseases, which has created a demand for more advanced diagnostics. Governments and healthcare organizations throughout the region are investing heavily to improve healthcare infrastructure, expand diagnostic capabilities, and support research initiatives. Moreover, growing emphasis on diseases surveillance and outbreak management and rising healthcare spending position Asia Pacific as one of the big contributors to growth in the entire market.

The break-up of the profile of primary participants in the molecular infectious disease testing market:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
By Designation: C-level - 27%, D-level - 18%, and Others - 55%
By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMerieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany).

Research Coverage:

This research report categorizes the molecular infectious disease testing market by product & service (reagents & kits, instruments, and services & software), by type (singleplex testing and multiplex testing), by test type (laboratory tests and point of car tests), by disease (respiratory infectious diseases (influenza, tuberculosis, pharyngitis, and other respiratory infectious diseases), gastrointestinal infectious diseases (hepatitis and other gastrointestinal infectious diseases), sexually transmitted diseases (human immunodeficiency virus, chlamydia trachomatis, neisseria gonorrhoea, syphilis, human papillomavirus, and other sexually transmitted diseases), vaginitis, meningitis, vector borne diseases, hospital-acquired infections, and other infectious diseases), by technology (polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, DNA sequencing & next generation sequencing, DNA microarrays, and other technologies), by end user (diagnostic laboratories, hospitals & clinics, and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular infectious disease testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular infectious disease testing market. Competitive analysis of upcoming startups in the molecular infectious disease testing market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular infectious disease testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (Rising burden of infectious diseases, rapid technological advancements in molecular diagnostics, growing funding for molecular testing), opportunities (High growth opportunities in emerging economies), restraints (Inconsistent reimbursement policies), and challenges (Changing regulatory landscape, operational barriers and labor shortage) influencing the growth of the molecular infectious disease testing market.
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular infectious disease testing market.
Market Development: Comprehensive information about lucrative markets - the report analyses the molecular infectious disease testing market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular infectious disease testing market.
Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMerieux (France), Hologic, Inc. (US), and Abbott (US).

1 INTRODUCTION

1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
- 1.3.2 INCLUSIONS AND EXCLUSIONS
- 1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
2.2 RESEARCH APPROACH
- 2.2.1 SECONDARY RESEARCH
  - 2.2.1.1 Key secondary sources
  - 2.2.1.2 Key data from secondary sources
  - 2.2.1.3 Objectives of secondary research
- 2.2.2 PRIMARY RESEARCH
  - 2.2.2.1 Key primary sources
  - 2.2.2.2 Key data from primary sources
  - 2.2.2.3 Objectives of primary research
  - 2.2.2.4 Key industry insights
  - 2.2.2.5 Breakdown of primary interviews
2.3 MARKET SIZE ESTIMATION
- 2.3.1 BOTTOM-UP APPROACH
  - 2.3.1.1 Company revenue estimation approach
  - 2.3.1.2 Presentations of companies and primary interviews
  - 2.3.1.3 Estimation of total molecular-based tests for HIV in US
  - 2.3.1.4 Growth forecast model
  - 2.3.1.5 CAGR projections
- 2.3.2 TOP-DOWN APPROACH
2.4 DATA TRIANGULATION
2.5 MARKET SHARE ANALYSIS
2.6 RESEARCH ASSUMPTIONS
- 2.6.1 PARAMETRIC ASSUMPTIONS
- 2.6.2 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW
4.2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029
4.3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024 VS. 2029
4.4 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024 VS. 2029
4.5 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024 VS. 2029
4.6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029
4.7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024 VS. 2029
4.8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
  - 5.2.1.1 Rising burden of infectious diseases
  - 5.2.1.2 Rapid technological advancements in molecular diagnostics
  - 5.2.1.3 Growing funding for molecular testing
- 5.2.2 RESTRAINTS
  - 5.2.2.1 Inconsistent reimbursement policies
- 5.2.3 OPPORTUNITIES
  - 5.2.3.1 High growth opportunities in emerging economies
- 5.2.4 CHALLENGES
  - 5.2.4.1 Changing regulatory landscape
  - 5.2.4.2 Operational barriers and labor shortage issues
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
- 5.4.1 INDICATIVE SELLING PRICE TREND, BY PRODUCT
- 5.4.2 INDICATIVE SELLING PRICE TREND OF SEXUALLY TRANSMITTED DISEASE TESTS, BY KEY PLAYER
- 5.4.3 INDICATIVE SELLING PRICE TREND OF GASTROINTESTINAL DISEASE TESTS, BY KEY PLAYER
- 5.4.4 INDICATIVE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
- 5.9.1 KEY TECHNOLOGIES
  - 5.9.1.1 Polymerase chain reaction
- 5.9.2 COMPLEMENTARY TECHNOLOGIES
  - 5.9.2.1 Isolated nucleic acid amplification technology
- 5.9.3 ADJACENT TECHNOLOGIES
  - 5.9.3.1 Next-generation sequencing
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
- 5.11.1 IMPORT DATA FOR HS CODE 3822
- 5.11.2 EXPORT DATA FOR HS CODE 3822
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
- 5.13.1 CASE STUDY 1: IMPROVED PATHOGEN-DIRECTED TREATMENT THROUGH RAPID SYNDROMIC PCR TESTING
- 5.13.2 CASE STUDY 2: CLINICAL IMPACT OF MULTIPLEX MOLECULAR DIAGNOSTIC TESTING IN CHILDREN WITH ACUTE GASTROENTERITIS
- 5.13.3 CASE STUDY 3: IMPACT OF MOLECULAR POINT OF CARE TESTING FOR GROUP A STREPTOCOCCUS PHARYNGITIS
5.14 REGULATORY LANDSCAPE
- 5.14.1 REGULATORY ANALYSIS
  - 5.14.1.1 NORTH AMERICA
    - 5.14.1.1.1 US
    - 5.14.1.1.2 Canada
  - 5.14.1.2 EUROPE
    - 5.14.1.2.1 Germany
    - 5.14.1.2.2 UK
    - 5.14.1.2.3 France
    - 5.14.1.2.4 Italy
  - 5.14.1.3 ASIA PACIFIC
    - 5.14.1.3.1 China
    - 5.14.1.3.2 Japan
    - 5.14.1.3.3 India
    - 5.14.1.3.4 Australia
  - 5.14.1.4 LATIN AMERICA
    - 5.14.1.4.1 Brazil
    - 5.14.1.4.2 Mexico
  - 5.14.1.5 MIDDLE EAST
    - 5.14.1.5.1 Africa
- 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.15 PORTER'S FIVE FORCES ANALYSIS
- 5.15.1 BARGAINING POWER OF SUPPLIERS
- 5.15.2 BARGAINING POWER OF BUYERS
- 5.15.3 THREAT OF NEW ENTRANTS
- 5.15.4 THREAT OF SUBSTITUTES
- 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
- 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.16.2 BUYING CRITERIA
5.17 IMPACT OF AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET
- 5.17.1 INTRODUCTION
- 5.17.2 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING APPLICATIONS
- 5.17.3 AI USE CASES
- 5.17.4 KEY COMPANIES IMPLEMENTING AI
- 5.17.5 FUTURE OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET

6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE

6.1 INTRODUCTION
6.2 REAGENTS & KITS
- 6.2.1 ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH
6.3 INSTRUMENTS
- 6.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO FOSTER GROWTH
6.4 SERVICES & SOFTWARE
- 6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH

7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE

7.1 INTRODUCTION
7.2 MULTIPLEX TESTING
- 7.2.1 RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH
7.3 SINGLEPLEX TESTING
- 7.3.1 NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH

8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE

8.1 INTRODUCTION
8.2 LABORATORY TESTS
- 8.2.1 INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH
8.3 POINT OF CARE TESTS
- 8.3.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET

9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE

9.1 INTRODUCTION
9.2 RESPIRATORY INFECTIOUS DISEASES
- 9.2.1 INFLUENZA
  - 9.2.1.1 Growing focus on faster diagnosis and control to propel market
- 9.2.2 TUBERCULOSIS
  - 9.2.2.1 Rise in undiagnosed and untreated cases to promote growth
- 9.2.3 PHARYNGITIS
  - 9.2.3.1 Need to differentiate between bacterial and viral infections to fuel growth
- 9.2.4 OTHER RESPIRATORY INFECTIOUS DISEASES
9.3 GASTROINTESTINAL INFECTIOUS DISEASES
- 9.3.1 HEPATITIS
  - 9.3.1.1 Rising government initiatives to expedite growth
- 9.3.2 OTHER GASTROINTESTINAL INFECTIOUS DISEASES
9.4 SEXUALLY TRANSMITTED DISEASES
- 9.4.1 HUMAN IMMUNODEFICIENCY VIRUS
  - 9.4.1.1 Increasing number of blood transfusions and blood donations to augment growth
- 9.4.2 HUMAN PAPILLOMAVIRUS
  - 9.4.2.1 Technological advancements for preventing human papillomavirus infections to drive market
- 9.4.3 CHLAMYDIA TRACHOMATIS
  - 9.4.3.1 Increasing development of molecular tests to aid growth
- 9.4.4 NEISSERIA GONORRHOEAE
  - 9.4.4.1 Increasing development of novel assays to boost market
- 9.4.5 SYPHILIS
  - 9.4.5.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market
- 9.4.6 OTHER SEXUALLY TRANSMITTED DISEASES
9.5 HOSPITAL-ACQUIRED INFECTIONS
- 9.5.1 GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET
9.6 VAGINITIS
- 9.6.1 INCREASING AWARENESS ABOUT WOMEN'S HEALTH TO BOLSTER GROWTH
9.7 MENINGITIS
- 9.7.1 RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH
9.8 VECTOR-BORNE DISEASES
- 9.8.1 GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET
9.9 OTHER INFECTIOUS DISEASES

10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY

10.1 INTRODUCTION
10.2 POLYMERASE CHAIN REACTION
- 10.2.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH
10.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
- 10.3.1 EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH
10.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
- 10.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET
10.5 IN SITU HYBRIDIZATION
- 10.5.1 NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET
10.6 DNA MICROARRAYS
- 10.6.1 NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO ENCOURAGE GROWTH
10.7 OTHER TECHNOLOGIES

11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER

11.1 INTRODUCTION
11.2 DIAGNOSTIC LABORATORIES
- 11.2.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET
11.3 HOSPITALS & CLINICS
- 11.3.1 RISING PATIENT VOLUME TO CONTRIBUTE TO GROWTH
11.4 OTHER END USERS

12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION

12.1 INTRODUCTION
12.2 NORTH AMERICA
- 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
- 12.2.2 US
  - 12.2.2.1 Presence of advanced healthcare infrastructure to augment growth
- 12.2.3 CANADA
  - 12.2.3.1 Favorable government initiatives to fuel market
12.3 EUROPE
- 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
- 12.3.2 GERMANY
  - 12.3.2.1 Increasing healthcare expenditure to advance growth
- 12.3.3 UK
  - 12.3.3.1 Growing number of diagnostic centers to fuel market
- 12.3.4 FRANCE
  - 12.3.4.1 Increasing demand for early disease diagnosis to augment growth
- 12.3.5 ITALY
  - 12.3.5.1 Growing adoption of advanced diagnostic technologies to fuel market
- 12.3.6 RUSSIA
  - 12.3.6.1 Increasing access to quality healthcare to facilitate growth
- 12.3.7 SPAIN
  - 12.3.7.1 Growing public health initiatives to boost market
- 12.3.8 REST OF EUROPE
12.4 ASIA PACIFIC
- 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
- 12.4.2 CHINA
  - 12.4.2.1 Rising public access to modern healthcare to spur growth
- 12.4.3 JAPAN
  - 12.4.3.1 Universal healthcare reimbursement policy to foster growth
- 12.4.4 INDIA
  - 12.4.4.1 Increased private and public investments to bolster growth
- 12.4.5 AUSTRALIA
  - 12.4.5.1 Growing investments for testing centers and treatment facilities to drive market
- 12.4.6 REST OF ASIA PACIFIC
12.5 LATIN AMERICA
- 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
- 12.5.2 BRAZIL
  - 12.5.2.1 Growing focus on improving healthcare infrastructure to fuel market
- 12.5.3 MEXICO
  - 12.5.3.1 Increasing accessibility and affordability of healthcare services to foster growth
- 12.5.4 REST OF LATIN AMERICA
12.6 MIDDLE EAST & AFRICA
- 12.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
- 12.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
12.7 GCC COUNTRIES
- 12.7.1 GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET
- 12.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

13 COMPETITIVE LANDSCAPE

13.1 INTRODUCTION
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
13.3 REVENUE ANALYSIS, 2021-2023
13.4 MARKET SHARE ANALYSIS, 2023
13.5 MARKET SHARE ANALYSIS OF EMEA REGION, 2023
13.6 COMPANY VALUATION AND FINANCIAL METRICS
13.7 BRAND/PRODUCT COMPARISON
13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 13.8.1 STARS
- 13.8.2 EMERGING LEADERS
- 13.8.3 PERVASIVE PLAYERS
- 13.8.4 PARTICIPANTS
- 13.8.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
  - 13.8.5.1 Company footprint
  - 13.8.5.2 Region footprint
  - 13.8.5.3 Product & service footprint
  - 13.8.5.4 Test type footprint
  - 13.8.5.5 Disease footprint
13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 13.9.1 PROGRESSIVE COMPANIES
- 13.9.2 RESPONSIVE COMPANIES
- 13.9.3 DYNAMIC COMPANIES
- 13.9.4 STARTING BLOCKS
- 13.9.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2023
  - 13.9.5.1 Detailed list of key startups/SMEs
  - 13.9.5.2 Competitive benchmarking of startups/SMEs
13.10 COMPETITIVE SCENARIO
- 13.10.1 PRODUCT LAUNCHES AND APPROVALS
- 13.10.2 DEALS

14 COMPANY PROFILES

14.1 KEY PLAYERS
- 14.1.1 DANAHER
  - 14.1.1.1 Business overview
  - 14.1.1.2 Products offered
  - 14.1.1.3 Recent developments
    - 14.1.1.3.1 Product launches and approvals
    - 14.1.1.3.2 Deals
    - 14.1.1.3.3 Expansions
  - 14.1.1.4 MnM view
    - 14.1.1.4.1 Right to win
    - 14.1.1.4.2 Strategic choices
    - 14.1.1.4.3 Weaknesses and competitive threats
- 14.1.2 F. HOFFMANN-LA ROCHE LTD
  - 14.1.2.1 Business overview
  - 14.1.2.2 Products offered
  - 14.1.2.3 Recent developments
    - 14.1.2.3.1 Product launches and approvals
    - 14.1.2.3.2 Deals
    - 14.1.2.3.3 Expansions
  - 14.1.2.4 MnM view
    - 14.1.2.4.1 Right to win
    - 14.1.2.4.2 Strategic choices
    - 14.1.2.4.3 Weaknesses and competitive threats
- 14.1.3 BIOMERIEUX
  - 14.1.3.1 Business overview
  - 14.1.3.2 Products offered
  - 14.1.3.3 Recent developments
    - 14.1.3.3.1 Product launches and approvals
    - 14.1.3.3.2 Deals
  - 14.1.3.4 MnM view
    - 14.1.3.4.1 Right to win
    - 14.1.3.4.2 Strategic choices
    - 14.1.3.4.3 Weaknesses and competitive threats
- 14.1.4 HOLOGIC, INC.
  - 14.1.4.1 Business overview
  - 14.1.4.2 Products offered
  - 14.1.4.3 Recent developments
    - 14.1.4.3.1 Product launches and approvals
    - 14.1.4.3.2 Deals
  - 14.1.4.4 MnM view
    - 14.1.4.4.1 Right to win
    - 14.1.4.4.2 Strategic choices
    - 14.1.4.4.3 Weaknesses and competitive threats
- 14.1.5 ABBOTT
  - 14.1.5.1 Business overview
  - 14.1.5.2 Products offered
  - 14.1.5.3 Recent developments
    - 14.1.5.3.1 Product launches and approvals
    - 14.1.5.3.2 Deals
  - 14.1.5.4 MnM view
    - 14.1.5.4.1 Right to win
    - 14.1.5.4.2 Strategic choices
    - 14.1.5.4.3 Weaknesses and competitive threats
- 14.1.6 THERMO FISHER SCIENTIFIC INC.
  - 14.1.6.1 Business overview
  - 14.1.6.2 Products offered
  - 14.1.6.3 Recent developments
    - 14.1.6.3.1 Product launches and approvals
    - 14.1.6.3.2 Deals
- 14.1.7 QIAGEN
  - 14.1.7.1 Business overview
  - 14.1.7.2 Products offered
  - 14.1.7.3 Recent developments
    - 14.1.7.3.1 Product launches and approvals
    - 14.1.7.3.2 Deals
    - 14.1.7.3.3 Expansions
- 14.1.8 REVVITY
  - 14.1.8.1 Business overview
  - 14.1.8.2 Products offered
- 14.1.9 GRIFOLS, S.A.
  - 14.1.9.1 Business overview
  - 14.1.9.2 Products offered
  - 14.1.9.3 Recent developments
    - 14.1.9.3.1 Product launches and approvals
    - 14.1.9.3.2 Deals
- 14.1.10 SEEGENE INC.
  - 14.1.10.1 Business overview
  - 14.1.10.2 Products offered
  - 14.1.10.3 Recent developments
    - 14.1.10.3.1 Product launches and approvals
    - 14.1.10.3.2 Deals
    - 14.1.10.3.3 Expansions
- 14.1.11 DIASORIN S.P.A.
  - 14.1.11.1 Business overview
  - 14.1.11.2 Products offered
  - 14.1.11.3 Recent developments
    - 14.1.11.3.1 Product launches and approvals
    - 14.1.11.3.2 Deals
- 14.1.12 SIEMENS HEALTHINEERS AG
  - 14.1.12.1 Business overview
  - 14.1.12.2 Products offered
  - 14.1.12.3 Recent developments
    - 14.1.12.3.1 Product launches and approvals
    - 14.1.12.3.2 Deals
    - 14.1.12.3.3 Expansions
- 14.1.13 BD
  - 14.1.13.1 Business overview
  - 14.1.13.2 Products offered
  - 14.1.13.3 Recent developments
    - 14.1.13.3.1 Product launches and approvals
    - 14.1.13.3.2 Deals
    - 14.1.13.3.3 Expansions
14.2 OTHER PLAYERS
- 14.2.1 QUIDELORTHO CORPORATION
- 14.2.2 BRUKER
- 14.2.3 GENETIC SIGNATURES
- 14.2.4 CO-DIAGNOSTICS, INC.
- 14.2.5 VELA DIAGNOSTICS
- 14.2.6 MOLBIO DIAGNOSTICS PVT. LTD.
- 14.2.7 SAVYON DIAGNOSTICS
- 14.2.8 UNIOGEN OY
- 14.2.9 GENEOMBIO TECHNOLOGIES
- 14.2.10 ADVANCED MOLECULAR DIAGNOSTICS
- 14.2.11 ALTONA DIAGNOSTICS GMBH
- 14.2.12 GENEFIRST LIMITED

15 APPENDIX

15.1 DISCUSSION GUIDE
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
15.3 CUSTOMIZATION OPTIONS
15.4 RELATED REPORTS
15.5 AUTHOR DETAILS

分子感染症検査の世界市場：製品・サービス別、タイプ別、検査タイプ別、疾患別、技術別、エンドユーザー別 - 予測（～2029年）

Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2029

目次

第1章イントロダクション

第2章調査手法

第3章エグゼクティブサマリー

第4章重要考察

第5章市場の概要

第6章分子感染症検査市場：製品・サービス別

第7章分子感染症検査市場：タイプ別

第8章分子感染症検査市場：検査タイプ別

第9章分子感染症検査市場：疾患別

第10章分子感染症検査市場：技術別

第11章分子感染症検査市場：エンドユーザー別

第12章分子感染症検査市場：地域別

第13章競合情勢

第14章企業プロファイル

第15章付録

List of Tables

List of Figures

The break-up of the profile of primary participants in the molecular infectious disease testing market:

Research Coverage:

Reasons to buy this report:

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE

7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE

8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE

9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE

10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY

11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER

12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION

13 COMPETITIVE LANDSCAPE

14 COMPANY PROFILES

15 APPENDIX

分子感染症検査の世界市場：製品・サービス別、タイプ別、検査タイプ別、疾患別、技術別、エンドユーザー別 - 予測（～2029年）

Molecular Infectious Disease Testing Market by Product & Service (Kits, Instruments), Type (Singleplex, Multiplex), Test Type (Lab, PoC), Disease (STD, Flu, GI, HAI), Technology (PCR, NGS), End User (Diagnostic Labs, Hospitals) - Global Forecast to 2029

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場の概要

第6章 分子感染症検査市場：製品・サービス別

第7章 分子感染症検査市場：タイプ別

第8章 分子感染症検査市場：検査タイプ別

第9章 分子感染症検査市場：疾患別

第10章 分子感染症検査市場：技術別

第11章 分子感染症検査市場：エンドユーザー別

第12章 分子感染症検査市場：地域別

第13章 競合情勢

第14章 企業プロファイル

第15章 付録

List of Tables

List of Figures

The break-up of the profile of primary participants in the molecular infectious disease testing market:

Research Coverage:

Reasons to buy this report:

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE

7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE

8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE

9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE

10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY

11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER

12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION

13 COMPETITIVE LANDSCAPE

14 COMPANY PROFILES

15 APPENDIX

第1章イントロダクション

第2章調査手法

第3章エグゼクティブサマリー

第4章重要考察

第5章市場の概要

第6章分子感染症検査市場：製品・サービス別

第7章分子感染症検査市場：タイプ別

第8章分子感染症検査市場：検査タイプ別

第9章分子感染症検査市場：疾患別

第10章分子感染症検査市場：技術別

第11章分子感染症検査市場：エンドユーザー別

第12章分子感染症検査市場：地域別

第13章競合情勢

第14章企業プロファイル

第15章付録